ALFA Finder| Margins | EBITDA margin compressed to 3.24% in Q4 from 9.25% YoY. |
|---|---|
| Management confidence | High |
Growth
FY26 revenue down 5% YoY to ₹47.47cr; EBITDA down 13% to ₹3.63cr; PAT surged 325% to ₹2.20cr.
Outlook
Focus on building a stronger financial foundation through operational efficiency and higher quality of earnings.
Risks
Q4 revenue degrowth of 8% and significant EBITDA margin contraction from 9.25% to 3.24% YoY.
Earnings Call filed with BSE, NSE: GUJTERC. Summary written with AI assistance from the document.
Gujarat Terce Laboratories Ltd: key numbers
- Share price
- ₹42.06
- Market cap
- ₹31.21 Cr
- Revenue (annual)
- ₹47.47 Cr
- Net profit (annual)
- ₹2.20 Cr
- P/E (TTM)
- 15.6×Sector 43.8×
- Promoter holding
- 40.03%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Terce Laboratories Ltd
All →Gujarat Terce Laboratories Acquisition Worth ₹3.23 Cr
Gujarat Terce Laboratories agreed to buy its corporate office premises 'Swati18' in Ahmedabad. The purchase is for Rs 3.23 Crore, excluding taxes and charges.
- Value
- ₹3.23 Cr
Gujarat Terce Laboratories Q2 FY27 Results: Net Profit ₹1.3 Cr, Down 7.1% YoY
Gujarat Terce approved unaudited standalone results for quarter and half year ended September 2026. Q2 profit was 131.92 lakhs against a Q1 loss of 17.81 lakhs.
- Key figure
- Net profit ₹1.3 Cr · -7.1% YoY
Gujarat Terce Laboratories Board Meeting Date
Gujarat Terce Laboratories will hold a board meeting on November 5, 2026 to consider unaudited standalone results for September 2026. The trading window stays closed until November 7, 2026.
Gujarat Terce Laboratories Other Announcement
Gujarat Terce Laboratories Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.
Gujarat Terce Laboratories Annual General Meeting
Gujarat Terce Laboratories held its 41st Annual General Meeting on August 21, 2026. Members passed resolutions regarding financial statements and director re-appointments.
Gujarat Terce Laboratories Management Change
Gujarat Terce Laboratories issued a corrigendum clarifying the re-appointment tenure of its MD & CEO, Mr. Aalap Prajapati, as three years instead of five.